{"prompt": "['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_597', 'MusiQoL (compare Baseline with after 6 and 12 months of Rebif treatment)', 'Reason/s for discontinuation of initial MS treatment (oral or injectable).', 'Additional Secondary Endpoints:', 'Correlation between TSQM V II and ARR; TSQM V II and adherence; TSQM V II and reason', 'for discontinuation', 'Correlation between MusiQoL and ARR; MusiQoL and adherence; MusiQoL and reason for', 'discontinuation', 'Correlation between TSQM V II subscales and adherence', 'Correlation between TSQM V II subscales and reasons for discontinuation', 'Difference between TSQM V II subscales at Baseline and after 6 and 12 months of Rebif', 'treatment', 'ARR before study entry compared to ARR at study end', 'Association between ARR and treatment adherence.', '9.1.2.3', 'Others', 'None', '9.2', 'Setting', 'This study will be conducted in 3 European countries: Belgium, Switzerland and the', 'Netherlands. In this study, the patients diagnosed with RRMS will be enrolled at around 33 sites', 'across Europe region.', '9.2.1', 'Study Population', 'RRMS patients who have discontinued their initial MS treatment and for whom MS treatment is', 'required according to the decision of the HCP and patient.', 'The study population will be identified according to the below inclusion and exclusion criteria.', 'Inclusion Criteria:', 'The patient can be included in the study when the patient', 'Is male or female, 18 to 65 years of age (both inclusive), at the time of informed consent', 'Is diagnosed with RRMS according to McDonald criteria 2010', 'Has discontinued treatment with dimethyl fumarate (Tecfidera), teriflunomide (Aubagio),', 'glatiramer acetate (Copaxone), intramuscular IFNB-1a (Avonex), pegylated interferon', '(Plegridy), subcutaneous IFNB-1b (Betaferon) or fingolimod (Gilenya) within 6 months prior', 'to Visit 1', 'CONFIDENTIAL', '24/60', 'INFORMATION', 'M']['Interferon beta-la', 'MESTRE-MS Study', \"EMR200136_59'\", 'Is currently treated with Rebif, using RebiSmart 2.0 for a maximum of 6 months prior to', 'Visit 1', 'Has a score on the Expanded Disability Status Scale (EDSS) between 0 to 5.0 inclusive', 'Is willing and able to give informed consent.', 'Exclusion Criteria:', 'The patient cannot be included when the patient', 'Has known planned surgical procedures at the time of the informed consent that will prevent', 'adherence to treatment with Rebif through RebiSmart 2.0', 'Is diagnosed with primary progressive, secondary progressive, or progressive relapsing MS', 'Is pregnant or lactating, or planning to become pregnant', 'In the opinion of the Investigator has significant renal or hepatic impairment or other', 'significant disease (e.g., cognitive or visual impairment) that would compromise adherence', 'and completion of the study', 'Reports any reason that he/she cannot complete the 1 year study', 'Has a history of hypersensitivity to natural or recombinant interferon, or any other component', 'of the formulation', 'Is contraindicated for the treatment with subcutaneous IFNB-1a therapy as per SmPC or', 'currently approved specific country product information', 'Has any other factor that in the opinion of the Investigator would make the subject unsuitable', 'for participation in this study', 'Have significant psychiatric symptoms that, in the opinion of the Investigator, would impact', 'patient ability to comply with treatment recommendations.', '9.2.2', 'Definition of Study Cohorts and Description of Treatments', 'There are no study cohorts in this study.', 'Treatment', 'Subjects will be treated with Rebif three times weekly, delivered through an electronic', 'autoinjector device (Rebismart 2.0). Treatment regimen will be as per Investigators routine', 'practice and in accordance with the licensed SmPC label or currently approved specific country', 'product information.', 'CONFIDENTIAL', '25/60', 'INFORMATION', 'M']\n\n###\n\n", "completion": "END"}